Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview

Respiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coron...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ahmed A. Al-Karmalawy, Raya Soltane, Ayman Abo Elmaaty, Mohamed A. Tantawy, Samar A. Antar, Galal Yahya, Amani Chrouda, Rami Adel Pashameah, Muhamad Mustafa, Mobarak Abu Mraheil, Ahmed Mostafa
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 SARS-CoV-2 management vaccines drug repurposing clinical trials Medicine R
Acceso en línea:	https://doaj.org/article/69118d28e17e4a4f880ab267d689adae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:69118d28e17e4a4f880ab267d689adae
record_format	dspace
spelling	oai:doaj.org-article:69118d28e17e4a4f880ab267d689adae2021-11-25T19:11:16ZCoronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview10.3390/vaccines91113172076-393Xhttps://doaj.org/article/69118d28e17e4a4f880ab267d689adae2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1317https://doaj.org/toc/2076-393XRespiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coronavirus disease 2019 (COVID-19), a mild-to-severe respiratory tract infection with frequent ability to give rise to fatal pneumonia in humans. The overwhelming outbreak of SARS-CoV-2 continues to unfold all over the world, urging scientists to put an end to this global pandemic through biological and pharmaceutical interventions. Currently, there is no specific treatment option that is capable of COVID-19 pandemic eradication, so several repurposed drugs and newly conditionally approved vaccines are in use and heavily applied to control the COVID-19 pandemic. The emergence of new variants of the virus that partially or totally escape from the immune response elicited by the approved vaccines requires continuous monitoring of the emerging variants to update the content of the developed vaccines or modify them totally to match the new variants. Herein, we discuss the potential therapeutic and prophylactic interventions including repurposed drugs and the newly developed/approved vaccines, highlighting the impact of virus evolution on the immune evasion of the virus from currently licensed vaccines for COVID-19.Ahmed A. Al-KarmalawyRaya SoltaneAyman Abo ElmaatyMohamed A. TantawySamar A. AntarGalal YahyaAmani ChroudaRami Adel PashameahMuhamad MustafaMobarak Abu MraheilAhmed MostafaMDPI AGarticleCOVID-19SARS-CoV-2managementvaccinesdrug repurposingclinical trialsMedicineRENVaccines, Vol 9, Iss 1317, p 1317 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 SARS-CoV-2 management vaccines drug repurposing clinical trials Medicine R
spellingShingle	COVID-19 SARS-CoV-2 management vaccines drug repurposing clinical trials Medicine R Ahmed A. Al-Karmalawy Raya Soltane Ayman Abo Elmaaty Mohamed A. Tantawy Samar A. Antar Galal Yahya Amani Chrouda Rami Adel Pashameah Muhamad Mustafa Mobarak Abu Mraheil Ahmed Mostafa Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
description	Respiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coronavirus disease 2019 (COVID-19), a mild-to-severe respiratory tract infection with frequent ability to give rise to fatal pneumonia in humans. The overwhelming outbreak of SARS-CoV-2 continues to unfold all over the world, urging scientists to put an end to this global pandemic through biological and pharmaceutical interventions. Currently, there is no specific treatment option that is capable of COVID-19 pandemic eradication, so several repurposed drugs and newly conditionally approved vaccines are in use and heavily applied to control the COVID-19 pandemic. The emergence of new variants of the virus that partially or totally escape from the immune response elicited by the approved vaccines requires continuous monitoring of the emerging variants to update the content of the developed vaccines or modify them totally to match the new variants. Herein, we discuss the potential therapeutic and prophylactic interventions including repurposed drugs and the newly developed/approved vaccines, highlighting the impact of virus evolution on the immune evasion of the virus from currently licensed vaccines for COVID-19.
format	article
author	Ahmed A. Al-Karmalawy Raya Soltane Ayman Abo Elmaaty Mohamed A. Tantawy Samar A. Antar Galal Yahya Amani Chrouda Rami Adel Pashameah Muhamad Mustafa Mobarak Abu Mraheil Ahmed Mostafa
author_facet	Ahmed A. Al-Karmalawy Raya Soltane Ayman Abo Elmaaty Mohamed A. Tantawy Samar A. Antar Galal Yahya Amani Chrouda Rami Adel Pashameah Muhamad Mustafa Mobarak Abu Mraheil Ahmed Mostafa
author_sort	Ahmed A. Al-Karmalawy
title	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
title_short	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
title_full	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
title_fullStr	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
title_full_unstemmed	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
title_sort	coronavirus disease (covid-19) control between drug repurposing and vaccination: a comprehensive overview
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/69118d28e17e4a4f880ab267d689adae
work_keys_str_mv	AT ahmedaalkarmalawy coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT rayasoltane coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT aymanaboelmaaty coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT mohamedatantawy coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT samaraantar coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT galalyahya coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT amanichrouda coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT ramiadelpashameah coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT muhamadmustafa coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT mobarakabumraheil coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview AT ahmedmostafa coronavirusdiseasecovid19controlbetweendrugrepurposingandvaccinationacomprehensiveoverview
_version_	1718410220513787904

Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview

Ejemplares similares